시장보고서
상품코드
1150075

세계의 지중해빈혈 시장-시장 점유율, 규모, 동향, 산업 분석 : 치료 유형별, 최종 용도별, 질환 유형별, 지역별, 부문 예측(2022-2030년)

Thalassemia Market Share, Size, Trends, Industry Analysis Report, By Treatment Type (Iron Chelating Drugs, Blood Transfusions, Folic Acid Supplements, Gene Therapy, Others); By End-Use; By Disease Type; By Region; Segment Forecast, 2022 - 2030

발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 117 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 지중해빈혈 시장 규모는 2030년까지 1조 4,929억 달러에 달할 것으로 예측됩니다.

세계의 지중해빈혈(Thalassemia) 시장을 조사했으며, 시장 개요/시장 규모 및 예측/동향/촉진 요인·억제 요인/치료 유형별·최종 용도별·질환 유형별·지역별 등 분석/기업 개요 등 정보를 제공합니다.

목차

제1장 소개

  • 리포트 설명
    • 조사의 목적
    • 시장 범위
    • 전제 조건
  • 이해관계자

제2장 주요 요약

  • 시장의 하이라이트

제3장 조사 방법

  • 개요
    • 데이터 마이닝
  • 정보원
    • 1차 정보
    • 2차 정보

제4장 세계의 지중해빈혈 시장 통찰

  • 지중해빈혈-산업 스냅샷
  • 지중해빈혈 시장 역학
    • 촉진 요인과 기회
    • 억제 요인과 과제
  • Porter’s Five Forces
    • 공급기업의 협상력
    • 신규 참가자의 위협
    • 구매자의 협상력
    • 대체품의 위협
    • 기존 기업 간의 경쟁력
  • PESTEL 분석
  • 지중해빈혈 시장의 산업 동향
  • 밸류체인 분석
  • COVID-19 영향 분석

제5장 세계의 지중해빈혈 시장 : 치료 유형별

  • 주요 조사 결과
  • 소개
    • 세계의 지중해빈혈 시장, 치료 유형별(2018-2030년)
  • 철 킬레이트 약물
    • 세계의 지중해빈혈 시장, 철 킬레이트 약물별, 지역별(2018-2030년)
  • 수혈
    • 세계의 지중해빈혈 시장, 수혈별, 지역별(2018-2030년)
  • 엽산 보충제
    • 세계의 지중해빈혈 시장, 엽산 보충제별, 지역별(2018-2030년)
  • 유전자 치료
    • 세계의 지중해빈혈 시장, 유전자 치료별, 지역별(2018-2030년)
  • 기타
    • 세계의 지중해빈혈 시장, 기타별, 지역별(2018-2030년)

제6장 세계의 지중해빈혈 시장 : 질환 유형별

  • 주요 조사 결과
  • 소개
    • 세계의 지중해빈혈 시장, 질환 유형별(2018-2030년)
  • 알파
    • 세계의 지중해빈혈 시장, 알파별, 지역별(2018-2030년)
  • 베타
    • 세계의 지중해빈혈 시장, 베타별, 지역별(2018-2030년)

제7장 세계의 지중해빈혈 시장 : 최종 용도별

  • 주요 조사 결과
  • 소개
    • 세계의 지중해빈혈 시장, 최종 용도별(2018-2030년)
  • 병원
    • 세계의 지중해빈혈 시장, 병원별, 지역별(2018-2030년)
  • 연구기관
    • 세계의 지중해빈혈 시장, 연구기관별, 지역별(2018-2030년)
  • 기타
    • 세계의 지중해빈혈 시장, 기타별, 지역별(2018-2030년)

제8장 세계의 지중해빈혈 시장 : 지역별

  • 주요 조사 결과
  • 소개
    • 지역 시장의 평가, 지역별(2018-2030년)
  • 지중해빈혈 시장-북미
    • 북미 : 지중해빈혈 시장, 치료 유형별(2018-2030년)
    • 북미 : 지중해빈혈 시장, 최종 용도별(2018-2030년)
    • 북미 : 지중해빈혈 시장, 질환 유형별(2018-2030년)
    • 지중해빈혈 시장-미국
    • 지중해빈혈 시장-캐나다
  • 지중해빈혈 시장-유럽
    • 유럽 : 지중해빈혈 시장, 치료 유형별(2018-2030년)
    • 유럽 : 지중해빈혈 시장, 최종 용도별(2018-2030년)
    • 유럽 : 지중해빈혈 시장, 질환 유형별(2018-2030년)
    • 지중해빈혈 시장-영국
    • 지중해빈혈 시장-프랑스
    • 지중해빈혈 시장-독일
    • 지중해빈혈 시장-이탈리아
    • 지중해빈혈 시장-스페인
    • 지중해빈혈 시장-네덜란드
    • 지중해빈혈 시장-러시아
  • 지중해빈혈 시장-아시아 태평양
    • 아시아 태평양 : 지중해빈혈 시장, 치료 유형별(2018-2030년)
    • 아시아 태평양 : 지중해빈혈 시장, 최종 용도별(2018-2030년)
    • 아시아 태평양 : 지중해빈혈 시장, 질환 유형별(2018-2030년)
    • 지중해빈혈 시장-중국
    • 지중해빈혈 시장-인도
    • 지중해빈혈 시장-말레이시아
    • 지중해빈혈 시장-일본
    • 지중해빈혈 시장-인도네시아
    • 지중해빈혈 시장-한국
  • 지중해빈혈 시장-중동·아프리카
    • 중동·아프리카 : 지중해빈혈 시장, 치료 유형별(2018-2030년)
    • 중동·아프리카 : 지중해빈혈 시장, 최종 용도별(2018-2030년)
    • 중동·아프리카 : 지중해빈혈 시장, 질환 유형별(2018-2030년)
    • 지중해빈혈 시장-사우디 아라비아
    • 지중해빈혈 시장-아랍 에미리트 연방
    • 지중해빈혈 시장-이스라엘
    • 지중해빈혈 시장-남아프리카
  • 지중해빈혈 시장-남미
    • 남미 : 지중해빈혈 시장, 치료 유형별(2018-2030년)
    • 남미 : 지중해빈혈 시장, 최종 용도별(2018-2030년)
    • 남미 : 지중해빈혈 시장, 질환 유형별(2018-2030년)
    • 지중해빈혈 시장-멕시코
    • 지중해빈혈 시장-브라질
    • 지중해빈혈 시장-아르헨티나

제9장 경쟁 상황

  • 확대·인수 분석
    • 확대
    • 인수
  • 파트너십/협업/협정/공개

제10장 기업 개요

  • ApoPharma Inc.
  • Acceleron Pharma, Inc.
  • Bluebird Bio Corporation
  • Bellicum Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Fresenius Kabi AG
  • GlaxoSmithKline plc
  • IONIS Pharmaceuticals
  • Kiadis Pharma
  • Lonza Group Ltd.
  • La Jolla Pharmaceutical Company
  • Novartis AG
  • Pfizer, Inc.
  • SG Pharma Pvt. Lmt.
  • Sangamo Therapeutics
  • Vifor Pharma
LYJ 22.11.30

The global thalassemia market size is expected to reach USD 1,492.9 billion by 2030, according to a new study by Polaris Market Research. The report "Thalassemia Market Share, Size, Trends, Industry Analysis Report, By Treatment Type (Iron Chelating Drugs, Blood Transfusions, Folic Acid Supplements, Gene Therapy, and Others); By Disease Type; By End-Use; By Region; Segment Forecast, 2022-2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The primary drivers driving market growth include rising thalassemia prevalence and increased thalassemia treatment awareness. According to the National Institute Health study report states that as per the Thalassemia International Federation, roughly 7.0% of the world's population suffers from hemoglobin-based diseases and conditions, with approximately 70.0% having sickle cell anemia and the remainder developing thalassemia. Thalassemia affects around 2.1% of the world's population.

Furthermore, as per the Medical Science Study, thalassemia affects roughly 4.4 out of every 10,000 live births worldwide. Since it maintains an autosomal mode of inheritance with no predilection for gender, either males or females receive the relevant gene variants equally. Approximately 5% of the global population possesses a variant in the alpha or beta component of the hemoglobin molecule. Just 1.7% of the world's population has symptoms caused by genetic mutations, which are classified as a thalassemia trait.

However, certain ethnic groups are more prone to be affected, with 5% to 30% of these populations suffering thalassemia indications. Thus, the rising prevalence of the disease has led to an increase in the demand for treatment which is boosting the market growth over the forecast period.

Moreover, the availability of therapies for the treatment of disease with its benefits is boosting the market growth over the forecast period. Chelation therapy and blood transfusions are the most common therapies for thalassemia patients because they are less expensive and more widely available than bone marrow transplants.

Chelation therapy employs medications such as widely prescribed to treat chronic iron overload that occurs following many blood transfusions in people with chronic thalassemia. Chelation therapy medicines used subcutaneously or intravenously using a gradual infusion approach to purify blood improve patients' chances of curing thalassemia. However, the expensive cost of the treatment is a key impediment to market growth.

Thalassemia Market Report Highlights

Blood Transfusions segment is anticipated to grow at a significant CAGR over the forecast period. The expanding market for marrow transplant and blood transfusion therapy, the increasing number of transfusion-dependent patients, and the realization of affordable treatment methods for thalassemia is projected to fuel market expansion.

gene therapy segment accounted for the largest share of the global revenue due to the rise in prevalence of thalassemia disease across the globe.

Asia Pacific is expected to grow at a witness fastest growth over the projected period. The existence of a substantial number of sickle cell disease and thalassemia patients is projected to drive market expansion in the coming years. Supportive government measures targeted at increasing the standard of care provided to individuals with hemoglobinopathies are supporting the region's market growth.

The global market includes ApoPharma Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, IONIS Pharmaceuticals, Kiadis Pharma, La Jolla Pharmaceutical Company, Novartis AG, Pfizer, Inc., SG Pharma Pvt. Lmt., Sangamo Therapeutics, and Vifor Pharma

Polaris Market Research has segmented the Thalassemia market report based on treatment type, disease type, end-user, and region:

Thalassemia, Treatment Type Outlook (Revenue - USD Billion, 2018 - 2030)

Iron Chelating Drugs

Blood Transfusions

Folic Acid Supplements

Gene Therapy

Others

Thalassemia, Disease Type Outlook (Revenue - USD Billion, 2018 - 2030)

Alpha Thalassemia

Beta Thalassemia

Thalassemia, End-Use Outlook (Revenue - USD Billion, 2018 - 2030)

Hospital

Research Institute

Others

Thalassemia, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Thalassemia Market Insights

  • 4.1. Thalassemia - Industry Snapshot
  • 4.2. Thalassemia Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Prevalence of Thalassemia
      • 4.2.1.2. Increasing Awareness of Thalassemia Treatment
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost of Treatment
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Thalassemia Market Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Thalassemia Market, by Treatment Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • 5.3. Iron Chelating Drugs
    • 5.3.1. Global Thalassemia Market, by Iron Chelating Drugs, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Blood Transfusions
    • 5.4.1. Global Thalassemia Market, by Blood Transfusions, by Region, 2018 - 2030 (USD Billion)
  • 5.5. Folic Acid Supplements
    • 5.5.1. Global Thalassemia Market, by Folic Acid Supplements, by Region, 2018 - 2030 (USD Billion)
  • 5.6. Gene Therapy
    • 5.6.1. Global Thalassemia Market, by Gene Therapy, by Region, 2018 - 2030 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Thalassemia Market, by Others, by Region, 2018 - 2030 (USD Billion)

6. Global Thalassemia Market, by Disease Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 6.3. Alpha
    • 6.3.1. Global Thalassemia Market, by Alpha, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Beta
    • 6.4.1. Global Thalassemia Market, by Beta, by Region, 2018 - 2030 (USD Billion)

7. Global Thalassemia Market, by End-Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • 7.3. Hospital
    • 7.3.1. Global Thalassemia Market, by Hospital, by Region, 2018 - 2030 (USD Billion)
  • 7.4. Research Institute
    • 7.4.1. Global Thalassemia Market, by Research Institute, by Region, 2018 - 2030 (USD Billion)
  • 7.5. Others
    • 7.5.1. Global Thalassemia Market, by Others, by Region, 2018 - 2030 (USD Billion)

8. Global Thalassemia Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Thalassemia Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 8.3. Thalassemia Market - North America
    • 8.3.1. North America: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.3.2. North America: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.3.3. North America: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.3.4. Thalassemia Market - U.S.
      • 8.3.4.1. U.S.: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.3.4.2. U.S.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.3.4.3. U.S.: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.3.5. Thalassemia Market - Canada
      • 8.3.5.1. Canada: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.3.5.2. Canada.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.3.5.3. Canada: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.4. Thalassemia Market - Europe
    • 8.4.1. Europe: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.4.2. Europe.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.4.3. Europe: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.4.4. Thalassemia Market - UK
      • 8.4.4.1. UK: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.4.4.2. UK.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.4.3. UK: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.4.5. Thalassemia Market - France
      • 8.4.5.1. France: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.4.5.2. France.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.5.3. France: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.4.6. Thalassemia Market - Germany
      • 8.4.6.1. Germany: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.4.6.2. Germany.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.6.3. Germany: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.4.7. Thalassemia Market - Italy
      • 8.4.7.1. Italy: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.4.7.2. Italy.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.7.3. Italy: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.4.8. Thalassemia Market - Spain
      • 8.4.8.1. Spain: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.4.8.2. Spain.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.8.3. Spain: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.4.9. Thalassemia Market - Netherlands
      • 8.4.9.1. Netherlands: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.4.9.2. Netherlands.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.9.3. Netherlands: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.4.10. Thalassemia Market - Russia
      • 8.4.10.1. Russia: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.4.10.2. Russia.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.10.3. Russia: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.5. Thalassemia Market - Asia Pacific
    • 8.5.1. Asia Pacific: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.5.2. Asia Pacific.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.5.3. Asia Pacific: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.5.4. Thalassemia Market - China
      • 8.5.4.1. China: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.5.4.2. China.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.5.4.3. China: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.5.5. Thalassemia Market - India
      • 8.5.5.1. India: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.5.5.2. India.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.5.5.3. India: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.5.6. Thalassemia Market - Malaysia
      • 8.5.6.1. Malaysia: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.5.6.2. Malaysia.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.5.6.3. Malaysia: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.5.7. Thalassemia Market - Japan
      • 8.5.7.1. Japan: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.5.7.2. Japan.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.5.7.3. Japan: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.5.8. Thalassemia Market - Indonesia
      • 8.5.8.1. Indonesia: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.5.8.2. Indonesia.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.5.8.3. Indonesia: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.5.9. Thalassemia Market - South Korea
      • 8.5.9.1. South Korea: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.5.9.2. South Korea.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.5.9.3. South Korea: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.6. Thalassemia Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.6.2. Middle East & Africa.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.6.3. Middle East & Africa: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.6.4. Thalassemia Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.6.5. Thalassemia Market - UAE
      • 8.6.5.1. UAE: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.6.5.2. UAE.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.6.5.3. UAE: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.6.6. Thalassemia Market - Israel
      • 8.6.6.1. Israel: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.6.6.2. Israel.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.6.6.3. Israel: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.6.7. Thalassemia Market - South Africa
      • 8.6.7.1. South Africa: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.6.7.2. South Africa.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.6.7.3. South Africa: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.7. Thalassemia Market - Latin America
    • 8.7.1. Latin America: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.7.2. Latin America.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.7.3. Latin America: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.7.4. Thalassemia Market - Mexico
      • 8.7.4.1. Mexico: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.7.4.2. Mexico.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.7.4.3. Mexico: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.7.5. Thalassemia Market - Brazil
      • 8.7.5.1. Brazil: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.7.5.2. Brazil.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.7.5.3. Brazil: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.7.6. Thalassemia Market - Argentina
      • 8.7.6.1. Argentina: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.7.6.2. Argentina.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.7.6.3. Argentina: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. ApoPharma Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Acceleron Pharma, Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Bluebird Bio Corporation
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Bellicum Pharmaceuticals
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Teva Pharmaceutical Industries Ltd.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Fresenius Kabi AG
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. GlaxoSmithKline plc
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. IONIS Pharmaceuticals
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Kiadis Pharma
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Lonza Group Ltd.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. La Jolla Pharmaceutical Company
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Novartis AG
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Pfizer, Inc.
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. SG Pharma Pvt. Lmt.
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
  • 10.15. Sangamo Therapeutics
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Benchmarking
    • 10.15.4. Recent Development
  • 10.16. Vifor Pharma
    • 10.16.1. Company Overview
    • 10.16.2. Financial Performance
    • 10.16.3. Product Benchmarking
    • 10.16.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제